Literature DB >> 20008205

ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?

Ara Metjian1, Wendy Lim.   

Abstract

A 35-year-old female presents with a prolonged activated partial thromboplastin time (aPTT) on routine testing, which is found to be due to a lupus anticoagulant. She has no medical issues, no personal or family history of thrombosis, no history of pregnancy loss, and no symptoms suggestive of an underlying rheumatologic disorder. She is a non-smoker and does not take oral contraceptives. You are asked to provide recommendations regarding the need for primary thromboprophylaxis. As you begin your literature search, you formulate the following clinical question: "In asymptomatic patients with antiphospholipid antibodies, does primary prophylaxis prevent thrombotic complications?"

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008205     DOI: 10.1182/asheducation-2009.1.247

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  8 in total

1.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Pediatric SLE--towards a comprehensive management plan.

Authors:  Hermine I Brunner; Jennifer Huggins; Marisa S Klein-Gitelman
Journal:  Nat Rev Rheumatol       Date:  2011-03-08       Impact factor: 20.543

Review 3.  What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?

Authors:  Tzu-Fei Wang; Wendy Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  Systemic lupus erythematosus and thrombosis.

Authors:  Mario Bazzan; Antonella Vaccarino; Fabio Marletto
Journal:  Thromb J       Date:  2015-04-23

Review 5.  The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?

Authors:  Emmanuel J Favaloro; Richard C W Wong
Journal:  Auto Immun Highlights       Date:  2010-07-10

6.  Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?

Authors:  Christian A Devaux; Laurence Camoin-Jau; Jean-Louis Mege; Didier Raoult
Journal:  J Microbiol Immunol Infect       Date:  2021-01-05       Impact factor: 4.399

7.  Transmission of lupus anticoagulant by allogeneic stem cell transplantation.

Authors:  Mira Romany Massoud; Basem M William; Katrina Harrill; Brenda Wimpfheimer Cooper; Marcos de Lima; Alvin H Schmaier
Journal:  Rev Bras Hematol Hemoter       Date:  2014-05-29

8.  Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies.

Authors:  Carlos Tortosa; Oscar Cabrera-Marante; Manuel Serrano; José A Martínez-Flores; Dolores Pérez; David Lora; Luis Morillas; Estela Paz-Artal; José M Morales; Daniel Pleguezuelo; Antonio Serrano
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.